Close Menu

NEW YORK – Single-cell proteomics firm IsoPlexis said Tuesday that it has received a $2 million Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health.

The Phase 2 grant is for work the company is doing to analyze the proteomic responses of trafficking leukocytes in patients with Alzheimer's disease and related neurodegenerative conditions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

Apr
20
Sponsored by
Olink

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
20
Sponsored by
ACD

This webinar will present a research project that is using spatial transcriptomics to discern the molecular mechanisms underlying fear memory.